IN2015KN00015A - - Google Patents

Info

Publication number: IN2015KN00015A
Authority: IN; India
Prior art keywords: masp; inhibitory agent; disease; subject; administered
Prior art date: 2012-06-18

Application number

Other languages

English (en)

Inventor

Hans-Wilhelm Schwaeble

Gregory A Demopulos

Thomas Dudler

Patrick Gray

Original Assignee

Omeros Corp

Univ Leicester

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-06-18

Filing date

2013-06-18

Publication date

2015-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49769678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2015KN00015(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-06-18 Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp

2015-07-31 Publication of IN2015KN00015A publication Critical patent/IN2015KN00015A/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Diabetes (AREA)
Hematology (AREA)
Microbiology (AREA)
Mycology (AREA)
Endocrinology (AREA)
Ophthalmology & Optometry (AREA)
Tropical Medicine & Parasitology (AREA)
Rheumatology (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Toxicology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)

IN15KON2015 2012-06-18 2013-06-18 IN2015KN00015A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261661167P	2012-06-18	2012-06-18
PCT/US2013/046432 WO2013192240A2 (en)	2012-06-18	2013-06-18	Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders

Publications (1)

Publication Number	Publication Date
IN2015KN00015A true IN2015KN00015A (ja)	2015-07-31

Family

ID=49769678

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IN15KON2015 IN2015KN00015A (ja)	2012-06-18	2013-06-18

Country Status (27)

Country	Link
US (4)	US20130344073A1 (ja)
EP (4)	EP2861246B1 (ja)
JP (5)	JP6445972B2 (ja)
KR (4)	KR20150031298A (ja)
CN (4)	CN109908352A (ja)
AU (3)	AU2013277309B2 (ja)
BR (1)	BR112014031522A2 (ja)
CA (2)	CA3214532A1 (ja)
CL (2)	CL2014003455A1 (ja)
CY (1)	CY1124234T1 (ja)
DK (1)	DK2861246T3 (ja)
ES (1)	ES2864857T3 (ja)
HK (1)	HK1209623A1 (ja)
HR (1)	HRP20210559T1 (ja)
HU (1)	HUE053727T2 (ja)
IL (2)	IL236327B (ja)
IN (1)	IN2015KN00015A (ja)
LT (1)	LT2861246T (ja)
MX (4)	MX381048B (ja)
NZ (1)	NZ629473A (ja)
PL (1)	PL2861246T3 (ja)
PT (1)	PT2861246T (ja)
RS (1)	RS61755B1 (ja)
RU (2)	RU2019140356A (ja)
SI (1)	SI2861246T1 (ja)
WO (1)	WO2013192240A2 (ja)
ZA (1)	ZA201500094B (ja)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2010034015A2 (en)	2008-09-22	2010-03-25	The Regents Of The University Of Colorado, A Body Corporate	Modulating the alternative complement pathway
EP3287142B1 (en)	2011-04-08	2021-08-04	University Of Leicester	Methods for treating conditions associated with masp-2 dependent complement activation
US11236168B2 (en)	2012-08-24	2022-02-01	Chugai Seiyaku Kabushiki Kaisha	Mouse FcγammaRII-specific Fc antibody
US9217042B2 (en) *	2012-10-23	2015-12-22	Abbott Cardiovascular Systems Inc.	Method of reducing MACE in diabetic patients subsequent to stent placement
ES2964340T3 (es)	2013-03-15	2024-04-05	Omeros Corp	Métodos para generar anticuerpos portadores de péptidos bioactivos y composiciones que comprenden los mismos
US20140363433A1 (en)	2013-03-15	2014-12-11	Omeros Corporation	Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
CN113621057A (zh)	2013-04-02	2021-11-09	中外制药株式会社	Fc区变体
US20160053023A1 (en) *	2013-04-09	2016-02-25	Annexon, Inc.	Methods of treatment for neuromyelitis optica
EP3003372B1 (en)	2013-06-07	2019-10-09	Duke University	Inhibitors of complement factor h
FI3019240T3 (fi)	2013-07-09	2024-05-30	Annexon Inc	Anti-komplementtitekijä c1q -vasta-aineita ja niiden käyttöjä
AU2014337047B2 (en)	2013-10-17	2020-03-12	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
US10155983B2 (en)	2014-03-31	2018-12-18	Machaon Diagnostics, Inc.	Method of diagnosis of complement-mediated thrombotic microangiopathies
CN106687123A (zh) *	2014-06-05	2017-05-17	科罗拉多州大学评议会	Map44多肽和基于天然抗体的构建体及其用途
SI3215527T1 (sl)	2014-11-05	2025-04-30	Annexon, Inc.	Humanizirana protitelesa proti komplementnemu faktorju C1q in njihova uporaba
US10639307B2 (en)	2015-05-15	2020-05-05	Children's Medical Center Corporation	Methods relating to the diagnosis and treatment of preeclampsia comprising administration of ADAMTS13 polypeptides
CA2987976A1 (en) *	2015-06-03	2016-12-08	Coyne Ip Holdings, Llc	Methods for establishing threshold limits for a chemical or biological agent in a target species
WO2017035405A1 (en)	2015-08-26	2017-03-02	Achillion Pharmaceuticals, Inc.	Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en)	2015-08-26	2017-03-02	Achillion Pharmaceuticals, Inc.	Amide compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) *	2015-08-26	2017-12-06	Achillion Pharmaceuticals Inc	Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3340983B1 (en)	2015-08-26	2023-10-04	Achillion Pharmaceuticals, Inc.	Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
MX2018005165A (es) *	2015-11-09	2020-11-11	Omeros Corp	Métodos para el tratamiento de padecimientos asociados con la activacion del complemento dependiente de masp-2.
SG11201803703UA (en)	2015-11-24	2018-06-28	Annexon Inc	Anti-complement factor c1q fab fragments and uses thereof
CN108495652A (zh) *	2016-01-05	2018-09-04	莱斯特大学	用于抑制有需要的受试者的纤维化的方法
CN109152834A (zh) *	2016-03-31	2019-01-04	奥默罗斯公司	抑制有需要的受试者的血管发生的方法
JOP20170154B1 (ar) *	2016-08-01	2023-03-28	Omeros Corp	تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
JOP20170170B1 (ar)	2016-08-31	2022-09-15	Omeros Corp	صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
WO2018160891A1 (en)	2017-03-01	2018-09-07	Achillion Pharmaceutical, Inc.	Pharmaceutical compounds for treatment of medical disorders
WO2018160892A1 (en)	2017-03-01	2018-09-07	Achillion Pharmaceuticals, Inc.	Macrocyclic compounds for treatment of medical disorders
IL294069B2 (en)	2017-03-01	2023-11-01	Achillion Pharmaceuticals Inc	Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
WO2018186322A1 (en) *	2017-04-03	2018-10-11	Chugai Seiyaku Kabushiki Kaisha	Anti-masp-1 antibodies and methods of use
WO2019040453A1 (en) *	2017-08-25	2019-02-28	Omeros Corporation	HIGHLY CONCENTRATED MASP-2 INHIBITOR ANTIBODY FORMULATIONS WITH LOW VISCOSITY, KITS AND METHODS FOR TREATING SUBJECTS SUFFERING FROM ATYPICAL HEMOLYTIC SYNDROME
EP3710589A4 (en)	2017-11-14	2021-11-10	Chugai Seiyaku Kabushiki Kaisha	ANTI-C1S ANTIBODIES AND METHODS OF USE
MA52248A (fr) *	2018-04-13	2021-02-17	Chugai Pharmaceutical Co Ltd	Anticorps dirigés contre un composant du complément et procédés d'utilisation
WO2019231935A1 (en)	2018-05-29	2019-12-05	Omeros Corporation	Masp-2 inhibitors and methods of use
EA202190106A1 (ru) *	2018-06-22	2021-04-13	Омерос Корпорейшн	Композиции и способы ингибирования masp-2 для лечения различных тромботических заболеваний и расстройств
EP3846803A4 (en)	2018-09-06	2022-08-10	Achillion Pharmaceuticals, Inc.	Macrocyclic compounds for the treatment of medical disorders
CA3111810A1 (en)	2018-09-06	2020-03-12	Achillion Pharmaceuticals, Inc.	Morphic forms of dancopan
US11807627B2 (en)	2018-09-25	2023-11-07	Achillon Pharmaceuticals, Inc.	Morphic forms of complement factor D inhibitors
GB2583560A (en)	2018-12-11	2020-11-04	Admirx Inc	Fusion protein constructs for complement associated disease
CN113195472A (zh)	2018-12-17	2021-07-30	艾其林医药公司	用于治疗补体介导的病症的靶向给药
PE20220431A1 (es) *	2019-05-07	2022-03-29	Bayer Ag	Compuestos inhibidores de la masp y usos de estos
EP4069676A1 (en)	2019-12-04	2022-10-12	Omeros Corporation	Masp-2 inhibitors and methods of use
JP2023504543A (ja)	2019-12-04	2023-02-03	オメロスコーポレーション	Ｍａｓｐ－２阻害剤および使用方法
BR112022010881A2 (pt)	2019-12-04	2022-08-23	Omeros Corp	Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado a serina protease-2 associada à lectina de ligação ao manan
CN115052604A (zh)	2019-12-04	2022-09-13	奥默罗斯公司	Masp-2抑制剂和使用方法
CN112237630A (zh) *	2020-02-21	2021-01-19	中国人民解放军军事科学院军事医学研究院	针对masp-2、冠状病毒n蛋白或其结合的物质在制备冠状病毒所致疾病药物中的应用
TWI867422B (zh) *	2020-03-06	2024-12-21	美商奥默羅斯公司	用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法
BR112023002843A2 (pt)	2020-08-18	2023-03-14	Omeros Corp	Anticorpo isolado ou fragmento de ligação a antígeno do mesmo, molécula de ácido nucleico, vetor de clonagem ou cassete de expressão, célula, métodos para gerar um anticorpo isolado ou fragmento de ligação a antígeno do mesmo, para determinar a presença ou quantidade de fator d maduro e de pró-fator d em uma amostra de teste, para avaliar o grau de ativação do caminho alternativo de complemento (apc) em uma amostra de teste, para monitorar a eficácia de tratamento com um anticorpo inibidor de lectina serina protease 3 de ligação a manana ou fragmento de ligação a antígeno do mesmo e para tratar um sujeito mamífero sofrendo de ou em risco de desenvolver uma doença ou distúrbio do caminho alternativo, composição, substrato para o uso em um imunoensaio, kit para detectar a presença ou quantidade de fator d maduro em uma amostra de teste, composição farmacêutica, e, artigo de fabricação
CN115215937B (zh)	2021-04-15	2023-05-26	上海麦济生物技术有限公司	抗人masp-2抗体及其制备方法和应用
KR20240116540A (ko)	2021-12-10	2024-07-29	오메로스 코포레이션	Masp-2의 세린 프로테아제 도메인에 결합하는 치료 항체 및 이것의 용도
CN114989259B (zh) *	2022-05-27	2023-06-09	成都佩德生物医药有限公司	一种小分子肽Ped4及应用
WO2024118840A1 (en)	2022-11-30	2024-06-06	Omeros Corporation	Fused pyrimidines as masp-2 inhibitors
WO2024186766A1 (en) *	2023-03-03	2024-09-12	The City University Of New York	Use of extracellular vesicles as biomarkers for age-related macular degeneration
US20250122225A1 (en)	2023-10-06	2025-04-17	Omeros Corporation	Masp-2 inhibitors and methods of use

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4331647A (en)	1980-03-03	1982-05-25	Goldenberg Milton David	Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5211657A (en)	1988-11-07	1993-05-18	The United States Government As Represented By The Secretary Of The Department Of Health And Human Services	Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5549910A (en)	1989-03-31	1996-08-27	The Regents Of The University Of California	Preparation of liposome and lipid complex compositions
SG46445A1 (en)	1990-01-26	1998-02-20	Immunomedics Inc	Vaccines against cancer and infectious diseases
JP3218637B2 (ja)	1990-07-26	2001-10-15	大正製薬株式会社	安定なリポソーム水懸濁液
JP2958076B2 (ja)	1990-08-27	1999-10-06	株式会社ビタミン研究所	遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
WO1994013804A1 (en)	1992-12-04	1994-06-23	Medical Research Council	Multivalent and multispecific binding proteins, their manufacture and use
US5856121A (en)	1994-02-24	1999-01-05	Case Western Reserve University	Growth arrest homebox gene
US6074642A (en)	1994-05-02	2000-06-13	Alexion Pharmaceuticals, Inc.	Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5741516A (en)	1994-06-20	1998-04-21	Inex Pharmaceuticals Corporation	Sphingosomes for enhanced drug delivery
US5795587A (en)	1995-01-23	1998-08-18	University Of Pittsburgh	Stable lipid-comprising drug delivery complexes and methods for their production
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5738868A (en)	1995-07-18	1998-04-14	Lipogenics Ltd.	Liposome compositions and kits therefor
CA2391402A1 (en) *	1999-12-02	2001-06-07	Jens Christian Jensenius	Masp-3, a complement-fixing enzyme, and uses for it
SG98393A1 (en)	2000-05-19	2003-09-19	Inst Materials Research & Eng	Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
EP1344533B1 (en) *	2002-03-15	2006-08-23	Natimmune A/S	Pharmaceutical compositions comprising mannose binding lectin
US7297348B2 (en)	2002-07-19	2007-11-20	Omeros Corporation	Biodegradable triblock copolymers, synthesis methods therefore, and hydrogels and biomaterials made there from
US7666627B2 (en) *	2002-08-08	2010-02-23	Targetex Kft.	Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
AU2004216176B2 (en) *	2003-02-21	2008-04-03	Genentech, Inc.	Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
ATE501728T1 (de) *	2003-07-08	2011-04-15	Umc Utrecht Holding Bv	Therapeutische verwendung von lpi, einem inhibitor des lectinwegs in staphylokokken bei entzündungskrankheiten
US7919094B2 (en) *	2004-06-10	2011-04-05	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
HUE029437T2 (en) *	2004-06-10	2017-02-28	Omeros Corp	A method for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) *	2004-06-10	2014-09-23	Omeros Corporation	Methods for treating conditions associated with MASP-2 dependent complement activation
CN100518905C (zh) *	2004-11-02	2009-07-29	浙江欧美环境工程有限公司	折返式电除盐器
US7612181B2 (en)	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
CA2618482C (en)	2005-08-19	2014-10-07	Abbott Laboratories	Dual variable domain immunoglobin and uses thereof
ES2400306T3 (es) *	2005-10-21	2013-04-09	Catalyst Biosciences, Inc.	Proteasas modificadas que inhiben la activación del complemento
PL1991275T3 (pl) *	2006-03-08	2015-04-30	Archemix Llc	Aptamery wiążące dopełniacza i środki anty-C5 użyteczne w leczeniu zaburzeń ocznych
EP2152861B1 (en)	2007-05-31	2017-03-22	University of Washington	Inducible mutagenesis of target genes
AU2009313203B2 (en) *	2008-11-10	2015-08-27	Alexion Pharmaceuticals, Inc.	Methods and compositions for treating complement-associated disorders
RU2012102021A (ru) *	2009-06-23	2013-07-27	Алексион Фармасьютикалз, Инк.	Биспецифические антитела, которые связываются с белками комплемента
CN107513103A (zh) *	2009-07-17	2017-12-26	丹麦国家医院	作为补体激活的抑制剂的masp同种型
CA2777845C (en) *	2009-10-16	2017-08-01	Omeros Corporation	Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
JP6148013B2 (ja) *	2010-03-05	2017-06-14	リグショスピタレト	補体活性化のキメラ抑制分子
US8795973B2 (en) *	2010-11-29	2014-08-05	University of Leceister	Methods for identifying inhibitors of mannan-binding lectin associated serine protease (MASP) proteins and uses thereof
EP3287142B1 (en) *	2011-04-08	2021-08-04	University Of Leicester	Methods for treating conditions associated with masp-2 dependent complement activation
PL3366307T3 (pl) *	2012-04-06	2022-03-07	Omeros Corporation	Kompozycje i sposoby hamowania masp-1 i/lub masp-2 i/lub masp-3 do leczenia napadowej nocnej hemoglobinurii
JOP20170154B1 (ar) *	2016-08-01	2023-03-28	Omeros Corp	تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة

2013
- 2013-06-18 RS RS20210465A patent/RS61755B1/sr unknown
- 2013-06-18 EP EP13807326.7A patent/EP2861246B1/en active Active
- 2013-06-18 HK HK15110361.3A patent/HK1209623A1/xx unknown
- 2013-06-18 EP EP21152111.7A patent/EP3878865A3/en not_active Withdrawn
- 2013-06-18 HR HRP20210559TT patent/HRP20210559T1/hr unknown
- 2013-06-18 KR KR20157001304A patent/KR20150031298A/ko not_active Ceased
- 2013-06-18 MX MX2014015715A patent/MX381048B/es unknown
- 2013-06-18 CN CN201811331359.1A patent/CN109908352A/zh active Pending
- 2013-06-18 SI SI201331873T patent/SI2861246T1/sl unknown
- 2013-06-18 PL PL13807326T patent/PL2861246T3/pl unknown
- 2013-06-18 RU RU2019140356A patent/RU2019140356A/ru unknown
- 2013-06-18 PT PT138073267T patent/PT2861246T/pt unknown
- 2013-06-18 LT LTEP13807326.7T patent/LT2861246T/lt unknown
- 2013-06-18 DK DK13807326.7T patent/DK2861246T3/da active
- 2013-06-18 KR KR1020227022627A patent/KR20220100997A/ko not_active Ceased
- 2013-06-18 RU RU2015101230A patent/RU2709351C2/ru active
- 2013-06-18 EP EP22177615.6A patent/EP4119577A3/en active Pending
- 2013-06-18 IN IN15KON2015 patent/IN2015KN00015A/en unknown
- 2013-06-18 HU HUE13807326A patent/HUE053727T2/hu unknown
- 2013-06-18 JP JP2015518524A patent/JP6445972B2/ja active Active
- 2013-06-18 CN CN202210652007.6A patent/CN115040653A/zh active Pending
- 2013-06-18 CA CA3214532A patent/CA3214532A1/en active Pending
- 2013-06-18 CN CN201380044434.5A patent/CN104717975A/zh active Pending
- 2013-06-18 AU AU2013277309A patent/AU2013277309B2/en active Active
- 2013-06-18 CN CN202410989581.XA patent/CN118924900A/zh active Pending
- 2013-06-18 EP EP16150858.5A patent/EP3058951A1/en not_active Withdrawn
- 2013-06-18 KR KR1020207003537A patent/KR20200015952A/ko not_active Ceased
- 2013-06-18 BR BR112014031522A patent/BR112014031522A2/pt not_active Application Discontinuation
- 2013-06-18 ES ES13807326T patent/ES2864857T3/es active Active
- 2013-06-18 CA CA2875567A patent/CA2875567C/en active Active
- 2013-06-18 KR KR1020207027432A patent/KR102339315B1/ko active Active
- 2013-06-18 WO PCT/US2013/046432 patent/WO2013192240A2/en active Application Filing
- 2013-06-18 NZ NZ629473A patent/NZ629473A/en unknown
- 2013-06-18 US US13/921,139 patent/US20130344073A1/en not_active Abandoned
2014
- 2014-12-17 MX MX2020005700A patent/MX2020005700A/es unknown
- 2014-12-17 MX MX2019012909A patent/MX2019012909A/es unknown
- 2014-12-17 MX MX2024005899A patent/MX2024005899A/es unknown
- 2014-12-17 IL IL236327A patent/IL236327B/en active IP Right Grant
- 2014-12-18 CL CL2014003455A patent/CL2014003455A1/es unknown
2015
- 2015-01-07 ZA ZA2015/00094A patent/ZA201500094B/en unknown
2016
- 2016-12-22 CL CL2016003297A patent/CL2016003297A1/es unknown
2018
- 2018-06-15 AU AU2018204285A patent/AU2018204285B2/en active Active
- 2018-08-28 IL IL261436A patent/IL261436B/en unknown
- 2018-09-14 US US16/131,871 patent/US20190127484A1/en not_active Abandoned
- 2018-11-30 JP JP2018224961A patent/JP6771531B2/ja active Active
2020
- 2020-05-06 AU AU2020202999A patent/AU2020202999B2/en active Active
- 2020-09-29 JP JP2020163180A patent/JP2021006546A/ja active Pending
2021
- 2021-04-20 CY CY20211100342T patent/CY1124234T1/el unknown
- 2021-10-11 US US17/498,559 patent/US20220259325A1/en not_active Abandoned
2022
- 2022-04-01 JP JP2022062008A patent/JP2022084946A/ja active Pending
2023
- 2023-09-26 US US18/474,862 patent/US20240254257A1/en active Pending
2024
- 2024-04-24 JP JP2024070206A patent/JP2024099699A/ja active Pending

Also Published As

Publication number	Publication date
BR112014031522A2 (pt)	2017-08-01
MX2020005700A (es)	2020-09-25
HUE053727T2 (hu)	2021-07-28
HK1209623A1 (en)	2016-04-08
RU2709351C2 (ru)	2019-12-17
EP3878865A3 (en)	2021-12-08
KR20220100997A (ko)	2022-07-18
JP2021006546A (ja)	2021-01-21
KR20150031298A (ko)	2015-03-23
CA3214532A1 (en)	2013-12-27
WO2013192240A3 (en)	2014-07-03
CN104717975A (zh)	2015-06-17
CL2014003455A1 (es)	2015-04-10
US20190127484A1 (en)	2019-05-02
LT2861246T (lt)	2021-04-26
WO2013192240A2 (en)	2013-12-27
AU2020202999A1 (en)	2020-05-28
NZ728179A (en)	2021-12-24
JP2022084946A (ja)	2022-06-07
US20220259325A1 (en)	2022-08-18
MX2024005899A (es)	2024-05-30
CN109908352A (zh)	2019-06-21
KR102339315B1 (ko)	2021-12-15
EP4119577A3 (en)	2023-11-08
JP6771531B2 (ja)	2020-10-21
EP2861246A2 (en)	2015-04-22
EP3878865A2 (en)	2021-09-15
RS61755B1 (sr)	2021-05-31
CL2016003297A1 (es)	2017-06-02
AU2013277309A1 (en)	2015-01-22
MX381048B (es)	2025-04-01
US20240254257A1 (en)	2024-08-01
PT2861246T (pt)	2021-04-05
EP2861246A4 (en)	2016-03-23
ES2864857T3 (es)	2021-10-14
EP2861246B1 (en)	2021-01-20
ZA201500094B (en)	2019-08-28
JP2015521623A (ja)	2015-07-30
CN118924900A (zh)	2024-11-12
PL2861246T3 (pl)	2021-10-25
JP6445972B2 (ja)	2018-12-26
JP2024099699A (ja)	2024-07-25
US20130344073A1 (en)	2013-12-26
AU2018204285B2 (en)	2020-02-27
KR20200116164A (ko)	2020-10-08
CA2875567C (en)	2023-11-14
RU2019140356A (ru)	2020-01-27
NZ629473A (en)	2017-02-24
CA2875567A1 (en)	2013-12-27
AU2020202999B2 (en)	2022-03-24
SI2861246T1 (sl)	2021-08-31
AU2013277309B2 (en)	2018-03-29
RU2015101230A (ru)	2016-08-10
HRP20210559T1 (hr)	2021-05-14
CN115040653A (zh)	2022-09-13
KR20200015952A (ko)	2020-02-13
CY1124234T1 (el)	2022-05-27
IL261436B (en)	2021-08-31
IL236327B (en)	2019-02-28
MX2014015715A (es)	2016-02-05
JP2019048881A (ja)	2019-03-28
DK2861246T3 (en)	2021-04-26
EP3058951A1 (en)	2016-08-24
EP4119577A2 (en)	2023-01-18
IL236327A0 (en)	2015-02-26
MX2019012909A (es)	2020-12-10
IL261436A (en)	2018-11-04

Publication	Publication Date	Title
IN2015KN00015A (ja)	2015-07-31
NZ629675A (en)	2017-02-24	Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria
UA113165C2 (xx)	2016-12-26	Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
MX356865B (es)	2018-06-18	Nuevas soluciones terapéuticas para tratar la enfermedad de parkinson.
MX355065B (es)	2018-04-04	Método y dispositivo para conmutación de cámaras.
MX2015007479A (es)	2015-09-04	Tiazolidindionas ahorradoras de receptores activados proliferadores de peroxisoma (ppar) y combinaciones para el tratamiento de enfermedades neurodegenerativas.
NZ704247A (en)	2018-04-27	Compositions and treatment for eye diseases and disorders
HK1252978A1 (zh)	2019-06-06	用於治療神經肌肉病癥的化合物
EA201491199A1 (ru)	2014-11-28	Наночастицы, включающие металлические материал и материал оксида гафния, композиция и ее применение
IN2014CN03465A (ja)	2015-10-09
MX344238B (es)	2016-12-07	Compuestos de tetrazol y métodos para preparar y usar los mismos.
AU2012253759A8 (en)	2013-12-05	Tricyclic sulfonamide compounds and methods of making and using same
MX369385B (es)	2019-11-07	Productos para cicatrizar heridas tisulares.
BR112016013109A2 (pt)	2017-09-26	anticorpos de anti-siglec-8 e métodos de seu uso
MX362861B (es)	2019-02-20	Metodos y composiciones para tratar esclerosis multiple y trastornos relacionadods.
PH12014502218A1 (en)	2015-01-12	Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP3818991A3 (en)	2021-07-14	Compositions and methods for treating diseases
EA201590726A1 (ru)	2015-10-30	Лахинимод для уменьшения таламического поражения при рассеянном склерозе
MX2015008187A (es)	2016-02-05	Inhibidores de alk deuterados.
MX2015012741A (es)	2016-02-19	Palbociclib deuterado.
WO2012139069A3 (en)	2014-02-27	Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
MX342119B (es)	2016-09-14	2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2013002121A (es)	2013-04-03	Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX343589B (es)	2016-11-11	Leucotoxina e/d como agente anti-inflamatorio novedoso y microbicida.
CY1116158T1 (el)	2017-02-08	Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3